TNXP — Tonix Pharmaceuticals Holding Balance Sheet
0.000.00%
- $122.56m
- $31.27m
- $10.09m
- 29
- 25
- 35
- 19
Annual balance sheet for Tonix Pharmaceuticals Holding, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 77.1 | 179 | 120 | 24.9 | 98.8 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | — | — | 4.82 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 88 | 189 | 131 | 47.8 | 119 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9.83 | 51.5 | 94.5 | 94.9 | 42.8 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 98.2 | 241 | 226 | 154 | 163 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.82 | 21.7 | 18.2 | 18.9 | 18.3 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.5 | 22.2 | 18.5 | 48.9 | 23.3 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 87.6 | 219 | 207 | 106 | 140 |
Total Liabilities & Shareholders' Equity | 98.2 | 241 | 226 | 154 | 163 |
Total Common Shares Outstanding |